BREAST THERMOGRPHY $195 (Regularly $229) - MAKE AN APPOINTMENT TODAY TO FIND OUT THE STATUS OF YOUR BREAST HEALTH!
What Is Breast Thermography?
Digital Infrared Thermal Imaging (DITI)
Breast Thermography can detect abnormalities in breast tissue up to 10 years earlier than a mammogram. It takes years for a tumor to grow and the earliest possible indication of abnormality is needed to allow for the earliest possible treatment and intervention.
Thermography or Digital Infrared Thermal Imaging (DITI) is a 15 minute non-invasive test of physiology. DITI detects the subtle physiologic changes that accompany breast pathology, whether it is cancer, fibrocystic disease, an infection or a vascular disease. Inflammation, which generates heat, is the first sign of a disease process. If inflammation is discovered through thermography, lifestyle changes can be implemented well in advance of a serious problem. Diet, weight loss and detoxification, supplements, exercise, and natural hormone balancing can help address inflammation.
DITI is appropriate for younger women (under 50) whose denser breast tissue makes mammograms ineffective. All women will benefit with non-invasive, radiation and pressure free screenings designed to improve chances for detection of fast growing active tumors in the intervals between mammography screenings or when mammography is not indicated by screening guidelines. DITI is also an option for women with breast implants wishing to avoid breast compression and those wishing to avoid harmful radiation.
First, a baseline screening is performed and then a follow-up is done 3 months later to see if any changes have occurred. The images taken show your individual thermal fingerprint. Everyone has their own individual thermal fingerprint and the Certified Medical Thermologist reading your study will determine after your second exam if the results are normal for you or if changes have occurred. The only thing that can cause changes to your fingerprint is pathology. All patients thermograms are kept on record and form a baseline for all future routine evaluations.
FIBROCYSTIC
NORMAL EARLY STAGE MALIGNANCY
